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Abstract
Background: Citation bias occurs when positive trials involving a medical intervention receive more citations than
neutral or negative trials of similar quality. Several large clinical trials have studied the use of thrombolytic agents
for the treatment of acute ischemic stroke with differing results, thereby presenting an opportunity to assess these
trials for evidence of citation bias. We compared citation rates among positive, neutral, and negative trials of
alteplase (tPA) and other thrombolytic agents for stroke.
Methods: We used a 2014 Cochrane Review of thrombolytic therapy for the treatment of acute stroke to identify
non-pilot, English-language stroke trials published in MEDLINE-indexed journals comparing thrombolytic therapy
with control. We classified trials as positive if there was a statistically significant primary outcome difference favoring
the intervention, neutral if there was no difference in primary outcome, or negative for a significant primary
outcome difference favoring the control group. Trials were also considered negative if safety concerns supported
stopping the trial early. Using Scopus, we collected citation counts through 2015 and compared citation rates
according to trial outcomes.
Results: Eight tPA trials met inclusion criteria: two were positive, four were neutral, and two were negative. The
two positive trials received 9080 total citations, the four neutral trials received 4847 citations, and the two negative
trials received 1096 citations. The mean annual per-trial citation rates were 333 citations per year for positive trials,
96 citations per year for neutral trials, and 35 citations per year for negative trials. Trials involving other thrombolytic
agents were not cited as often, though as with tPA, positive trials were cited more frequently than neutral or
negative trials.
Conclusions: Positive trials of tPA for ischemic stroke are cited approximately three times as often as neutral trials,
and nearly 10 times as often as negative trials, indicating the presence of substantial citation bias.
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Background
Stroke is the second most frequent cause of death
globally [1]. Early thrombolytic treatment with alte-
plase (tPA) is one of the few therapies to be identified
that might improve stroke outcomes, and existing
guidelines overwhelmingly favor the use of tPA in se-
lected patients [2–4]. However, the use of tPA is
controversial because some clinical trials have shown
benefit, some have shown no effect, and some have
shown harm [5].
Importance
One factor that might influence the translation of evi-
dence into clinical practice is citation bias, the select-
ive citation of papers whose results support authors’
preconceived opinions regarding treatment efficacy.
Because citation bias often results in the dispropor-
tionate citation of studies with statistically significant
or “positive” results, it may result in a distortion of
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the perceived efficacy of medical treatments within
the published scientific literature [6]. Prior efforts to
characterize the presence of citation bias in the med-
ical literature have observed this form of bias among
studies of therapeutic interventions, with approxi-
mately twice as many citations for studies with statis-
tically significant results [7], but not among a broader
range of study types [8].
Goals of this investigation
We assessed for evidence of citation bias among clinical
trials of tPA and other thrombolytic agents in the treat-
ment of acute ischemic stroke.
Methods
Study design
This was a cross-sectional study of trials assessing intraven-
ously administered thrombolytic therapy as an intervention
for acute ischemic stroke.
Trial selection
We identified eligible trials using a 2014 Cochrane
Systematic Review of thrombolytics for ischemic stroke
[9]. The investigators of this systematic review utilized
a comprehensive strategy to search for trials of thrombo-
lytic agents for the treatment of ischemic stroke by
searching MEDLINE, EMBASE, the Cochrane Stroke
Group Trials Register, relevant conference proceed-
ings, manuscript reference lists, and by contacting
pharmaceutical companies and investigators known to
participate in thrombolytic research. Our primary
analysis included trials which compared tPA to pla-
cebo or open control for the treatment of ischemic
stroke. We focused primarily on tPA, as it is
currently the only Food and Drug Administration-
approved thrombolytic agent for acute stroke. A
secondary analysis included trials comparing thrombo-
lytic agents other than tPA (streptokinase, urokinase,
prourokinase, and desmotoplase) to controls. Trials
were excluded if they were not published in English,
not published in a MEDLINE-indexed journal, or if
they were pilot studies with fewer than 50 partici-
pants, as we hypothesized that these characteristics
would substantially impact citation counts.
Trial classification
Trials were classified as positive if the defined pri-
mary outcome met investigator-established criteria for
statistical significance favoring the intervention arm,
neutral if there was no significant primary outcome
difference, and negative if the primary outcome
showed a statistically significant effect favoring the
control arm, or if safety concerns supported halting
the trial early.
Outcomes and analysis
We collected annual citation counts through December
2015 using Scopus. Citation data were updated as of 6
January 2016. We compared cumulative citation counts
among positive, neutral, and negative trials graphically.
Annual citation rates were calculated by dividing the
total number of citations by the time elapsed from the
earlier of the print or online publication dates and the
end of 2015. Jadad quality scores were calculated by two
study authors for each of the included trials; discrepan-
cies were resolved by consensus [10]. We calculated the
Pearson correlation coefficient to assess the relationship
between trial size and annual citation rate. Data were
collected and analyzed using Excel (Microsoft Corp.,
Redmond, WA, USA) and PASW version 18.0 (SPSS
Inc, Chicago, IL, USA). The STROBE Statement check-
list for observational studies is included as an additional
file (see Additional file 1).
Results
Trial selection
Of the 27 thrombolytic trials identified in the 2014
Cochrane Review, 12 did not meet inclusion criteria: one
was not published in English; three were not indexed to
MEDLINE; and eight were pilot studies. The eight in-
cluded tPA trials were published between 1995 and
2012, six in major general medical journals and two in
specialty neurology journals. Seven trials investigated
thrombolytic agents other than tPA (Table 1).
Main results
The eight included tPA trials consisted of two reporting a
statistically significant benefit for the primary outcome
(positive trials) [11, 12], four that completed enrollment but
showed no benefit based on the primary outcome (neutral
trials) [13–16], and two that were stopped early due to
Safety Committee concerns (negative trials) [17, 18].
The two positive trials received 9080 total citations;
the four neutral trials received 4847 citations; and the
two negative trials received 1096 citations. Mean annual
per-trial citation rates were 333 per year for the positive
trials, 96 per year for the neutral trials, and 35 per year
for the negative trials. Figure 1 shows cumulative
citation counts for individual trials. Visual analysis of
these results shows that heterogeneity with respect to
the enrollment windows for the included trials does not
explain the observed differences in citation rates.
Seven trials that met the inclusion criteria involved
thrombolytic agents other than tPA, including streptokin-
ase, urokinase, prourokinase, and desmotoplase. Two were
positive (PROACT II [19], DIAS [20]), two were neutral
(DIAS-2 [21], MELT [22]), and three were stopped early
for harm (ASK [23], MAST-E [24], MAST-I [25]). The
positive trials received a mean of 112 citations per year,
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the neutral trials received a mean of 41 citations per year,
and the negative trials received a mean of 22 citations per
year (Fig. 2).
All of the included tPA trials had at least 100 partici-
pants. A total of 1445 participants were enrolled in the
positive trials of tPA, 4556 participants in neutral trials,
and 755 participants in negative trials. There was no
statistical relationship between the number of par-
ticipants in the trial and the number of citations per year
(r = 0.056; p = 0.90). For any given trial size, trials with
positive results had equal or more citations per year
than trials with neutral results, and trials with neutral
results had more citations than trials with negative
results (Fig. 3).
Discussion
We analyzed citation rates from eight major trials of
intravenously administered tPA and seven major trials
of other thrombolytic agents for the treatment of
acute ischemic stroke. Among the tPA trials, those
showing a statistically significant benefit from tPA
were cited more than three times as often as neutral
trials and nearly 10 times as often as negative trials.
Positive trials involving other thrombolytic agents
were also cited far more frequently than neutral or
negative trials. These results demonstrate the presence
of substantial citation bias.
While the factors influencing individual author deci-
sions about what studies to cite are likely quite varied,
the net effect of these various influences with respect to
tPA and other thrombolytics is to disproportionately cite
positive trials relative to neutral and negative trials. Over
time, this phenomenon has the potential to distort the
medical literature in several important ways. First, if
clinicians and policy-makers do not utilize a systematic
approach when reviewing the medical literature on a
given topic they are likely to be exposed to a biased
subset of all the potentially relevant trials. Second, as the
number of MEDLINE-indexed publications continues to
grow, the sheer number of included manuscripts will
make it more and more difficult to perform comprehen-
sive medical literature searches based on keywords
alone. As a result, readers are increasingly likely to
utilize citation webs as part of their medical literature
search strategies, potentially exacerbating any existing
citation bias. For example, the ranking algorithm from
Google Scholar puts great weight on the number of cita-
tions [26]. Additionally, citation counts are often used as
markers of the quality and impact of published research,
further emphasizing the results of highly cited, positive
trials as compared to those with fewer citations [27, 28].
When possible, preferential citation of high-quality
systematic reviews which utilize and report meticulous
search methods may help to limit citation bias due to
Table 1 Publication characteristics and citation rates for included trials of thrombolytics for stroke
Trial Year
published
Patients
enrolled
Location Journal Intervention Jadad
score
Result Total
citations
Citations
per year
NINDS [11] 1995 624 US NEJM IV tPA 5 Positive 6622 330
ECASS III [12] 2008 821 Europe NEJM IV tPA 5 Positive 2458 335
ECASS [13] 1995 620 Europe JAMA IV tPA 5 Neutral 2138 106
ECASS II [14] 1998 800 Europe, Australia, NZ Lancet IV tPA 5 Neutral 1768 102
EPITHET [15] 2008 101 Australia, NZ,
Belgium, UK
Lancet Neurology IV tPA 5 Neutral 561 72
IST-3 [16] 2012 3035 Europe, Canada,
Mexico, Australia
Lancet IV tPA 3 Neutral 380 104
ATLANTIS B [17] 1999 613 US, Canada JAMA IV tPA 5 Negative 820 51
ATLANTIS A [18] 2000 142 US Stroke IV tPA 5 Negative 276 18
PROACT II [19] 1999 180 US, Canada JAMA IA pro-urokinase 3 Positive 2287 142
DIAS [20] 2005 104 Europe, Australia,
Singapore
Stroke IV desmoteplase 5 Positive 749 69
DIAS-2 [21] 2009 193 Australia, Europe,
US, Canada,
China, Singapore
Lancet Neurology IV desmoteplase 5 Neutral 332 49
MELT [22] 2007 114 Japan Stroke IA urokinase 3 Neutral 282 34
ASK [23] 1996 340 Australia JAMA IV streptokinase 5 Negative 328 17
MAST-E [24] 1996 310 Europe NEJM IV streptokinase 5 Negative 421 22
MAST-I [25] 1995 622 Europe Lancet IV streptokinase 3 Negative 551 27
IA intra-arterial, IV intravenous, JAMA Journal of the American Medical Association, NEJM New England Journal of Medicine, NZ New Zealand, tPA alteplase, US
United States, UK United Kingdom
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the selective citation of individual trials. In particular, meta-
analyses using individual patient data allow for assessments
of both efficacy and safety outcomes with applicability be-
yond the confines of sometimes homogeneous individual
trial populations [29, 30].
Additionally, it is likely that journal impact factor has
a causal influence in the citation rates of the included
trials, and we considered adjusting our results based on
impact factor. However, there is also a likely causal rela-
tionship between the direction of study results and the
publishing journal [31]. Therefore, rather than function-
ing as a confounder, in this case impact factor is more
likely to be a mediator between the direction of trial
results and citation rate. As a result, adjusting for impact
factor would be expected to result in an underestimation
of the relationship between trial results and citation rate.
For this reason, we did not adjust our analysis for im-
pact factor of the publishing journals, though our
Table 1 lists the identity of the publishing journal for
each included trial.
Several limitations of this work should be considered
when interpreting these results. First, classification of trials
according to comparisons based on the primary outcome
measure is not always straightforward. For example, the
DIAS trial had multiple intervention groups and multiple
primary endpoints; we classified it as positive because sev-
eral of the analyses assessing these primary endpoints
showed results favoring one or more of the intervention
groups [20]. Similarly, the ATLANTIS B trial was stopped
early, with no between-group difference in the primary effi-
cacy outcome. However, rates of intracranial hemorrhage,
symptomatic intracranial hemorrhage, and fatal intracranial
Fig. 1 Citation rates of alteplase (tPA) trials for acute stroke. Cumulative citation counts over time for positive (solid lines), neutral (dashed lines),
and negative (dotted lines) randomized controlled trials of tPA for acute ischemic stroke
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hemorrhage were significantly higher in the intervention
group; there was a strong trend towards increased overall
90-day mortality in the intervention group (p = 0.09); and
in their conclusion the study authors describe their results
as “negative” [18]. Based on these factors we classified the
trial as negative.
An additional limitation is that we were unable to
assess the context in which citations were made. For
example, inclusion of a citation does not always mean
that the cited study is presented favorably, and to some
extent a high citation rate might be a marker of contro-
versy rather than influence. Similarly, we did not assess
in which journals studies were cited nor did we evaluate
references to studies in the lay press; some journals have
more influence on clinicians, researchers, and policy
than others and summaries of studies in the lay press
may also influence the impact of a study. Finally, while
many of the included trials were similar with respect to
sample size, publication date, and publication in a high-
impact journal, it is likely that other study characteris-
tics, including geographic location and author group,
also influenced citation rates. Importantly, however, it is
unlikely that the timing of tPA administration alone
explains the observed differences in citation rate. For
example, the IST-3 trial enrolled more patients in the 0–
3-hour window than the NINDS trial [11, 16], and more
patients in the 3–4.5-hour window than the ECASS III
trial [12], yet the citation curve for IST-3 is consistent
with the curves of the other neutral trials rather than
the curves observed for these two positive trials. Like-
wise, the enrollment windows for the ECASS III trial (3
to 4.5 hours) [12] and the ATLANTIS B trial (3 to 5
hours) [18] were similar, yet the annual citation rate for
ECASS III is over six times that of ATLANTIS B.
Fig. 2 Citation rates of non-alteplase (non-tPA) thrombolytic trials for acute stroke. Cumulative citation counts over time for positive (solid lines), neutral
dashed lines), and negative (dotted lines) randomized controlled trials of thrombolytic agents other than tPA for acute ischemic stroke
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Conclusions
Reducing citation bias requires vigilance on the part of
authors, editors, and peer reviewers but the available
evidence suggests that citation bias is rarely identified
during the review process [32]. Routine reliance on
systematic literature reviews, when possible, may help to
limit citation bias, though more work is needed to
develop and test approaches which reduce the selective
citation of medical research.
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